Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug ...

Dis-Chem Pharmacies Limited is inviting applications for a Post Basic Qualified Pharmacist Assistant at its Dainfern store in ...

Manish Sabharwal and Sundeep Khanna's 'Made in India' is the untold story of Desh Bandhu Gupta, Lupin, and how India became ...

A growing cohort without protective immunity, combined with measles’ high basic transmissibility, enables rapid propagation ...

Ireland’s economic-development policies in the second half of the 20th century, many designed to keep industry ownership native hands, presented little encouragement for overseas companies to invest ...

Chinese Vice-Premier Liu Guozhong, also a member of the Political Bureau of the Communist Party of China Central Committee, visits Peking University's School of Pharmaceutical Sciences in Beijing, ...

If last year’s pharma ad showing during the Super Bowl drove buzzy conversation and a touch of controversy, the lasting impression pharma marketers made on consumers during Sunday’s Super Bowl LX took ...

Pharma is having its moment in Super Bowl 60. After increasing interest from the category over the past two years, Sunday is set to arguably be the biggest advertising day in the industry’s history.

The Trump administration is delaying the release of TrumpRx, an online platform that lets people buy prescription drugs directly from pharmaceutical companies at a discount, according to Politico.

SpyGlass Pharma, Inc. (SGP) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information, although the final amount may differ. The biopharma is a ...

India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company. If it goes through, the deal that ...

Drug development is notoriously failure-prone. Only one in every ten drug candidates that enter human trials eventually goes onto the market. Turning a promising molecule into a useful medicine ...